Bayesian network meta-analysis of five first-line regimens in advanced gastric/GEJ adenocarcinoma: zolbetuximab plus chemotherapy had similar or numerically favourable OS and PFS vs immune checkpoint inhibitors at PD-L1 CPS 1–<10, but numerically worse at CPS ≥10.
Meta-analysis
Shitara et al. Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysis